PURPOSE: Patients treated for pituitary adenomas generally report a reduced quality of life (QoL). At present, the patient's perspective of QoL has not been fully addressed and this, and further insight in potential determinants of QoL in pituitary diseases is required to design strategies to improve QoL. We aimed to define patients' perceived QoL and to identify potential factors they perceive to contribute to QoL. METHODS: We conducted four independent focus groups of six patients each, per specific pituitary disease (Cushing's disease, Non-functioning pituitary macroadenoma, acromegaly, prolactinoma). In two sessions these focus groups discussed aspects of QoL. Verbatim transcripts were analyzed using a grounded theory approach. RESULTS: The issues raised by the patient groups were compatible with statements and items of available QoL questionnaires. In addition, other QoL aspects emerged, such as visual limitations (physical problems); issues with a desire to have children/family planning, fear of collapsing, fear of recurrence, panic, persisting thoughts, problems with an altered personality, anger, jealousy, sadness, frustration (psychological problems); and difficulties communicating about the disease, lack of sympathy and understanding by others, and a reduced social network (social problems). Next, this study uncovered factors which might contribute to a decreased QoL (e.g. less effective coping strategies, negative illness perceptions, negative beliefs about medicines, unmet needs regarding care). CONCLUSIONS: This focus group study demonstrated that important disease-specific aspects of QoL are neglected in current pituitary disease-specific questionnaires and elucidated potential factors that contribute to a decreased QoL. Information provided in this study can (and will) be used for developing additional items for disease-specific QoL questionnaires and for the development of a self-management intervention aiming to improve QoL in patients treated for pituitary diseases.
PURPOSE:Patients treated for pituitary adenomas generally report a reduced quality of life (QoL). At present, the patient's perspective of QoL has not been fully addressed and this, and further insight in potential determinants of QoL in pituitary diseases is required to design strategies to improve QoL. We aimed to define patients' perceived QoL and to identify potential factors they perceive to contribute to QoL. METHODS: We conducted four independent focus groups of six patients each, per specific pituitary disease (Cushing's disease, Non-functioning pituitary macroadenoma, acromegaly, prolactinoma). In two sessions these focus groups discussed aspects of QoL. Verbatim transcripts were analyzed using a grounded theory approach. RESULTS: The issues raised by the patient groups were compatible with statements and items of available QoL questionnaires. In addition, other QoL aspects emerged, such as visual limitations (physical problems); issues with a desire to have children/family planning, fear of collapsing, fear of recurrence, panic, persisting thoughts, problems with an altered personality, anger, jealousy, sadness, frustration (psychological problems); and difficulties communicating about the disease, lack of sympathy and understanding by others, and a reduced social network (social problems). Next, this study uncovered factors which might contribute to a decreased QoL (e.g. less effective coping strategies, negative illness perceptions, negative beliefs about medicines, unmet needs regarding care). CONCLUSIONS: This focus group study demonstrated that important disease-specific aspects of QoL are neglected in current pituitary disease-specific questionnaires and elucidated potential factors that contribute to a decreased QoL. Information provided in this study can (and will) be used for developing additional items for disease-specific QoL questionnaires and for the development of a self-management intervention aiming to improve QoL in patients treated for pituitary diseases.
Authors: S D Dorn; L Hernandez; M T Minaya; C B Morris; Y Hu; J Leserman; S Lewis; A Lee; S I Bangdiwala; P H R Green; D A Drossman Journal: Aliment Pharmacol Ther Date: 2009-12-15 Impact factor: 8.171
Authors: Jitske Tiemensma; Adrian A Kaptein; Alberto M Pereira; Johannes W A Smit; Johannes A Romijn; Nienke R Biermasz Journal: J Clin Endocrinol Metab Date: 2011-09-14 Impact factor: 5.958
Authors: O M Dekkers; A A van der Klaauw; A M Pereira; N R Biermasz; P J Honkoop; F Roelfsema; J W A Smit; J A Romijn Journal: J Clin Endocrinol Metab Date: 2006-06-20 Impact factor: 5.958
Authors: Agatha A van der Klaauw; Olaf M Dekkers; Alberto M Pereira; Klaas W van Kralingen; Johannes A Romijn Journal: J Clin Endocrinol Metab Date: 2007-07-31 Impact factor: 5.958
Authors: Agatha A van der Klaauw; Nienke R Biermasz; Hendrieke C Hoftijzer; Alberto M Pereira; Johannes A Romijn Journal: Clin Endocrinol (Oxf) Date: 2008-07-01 Impact factor: 3.478
Authors: Cornelie D Andela; Margreet Scharloo; Alberto M Pereira; Ad A Kaptein; Nienke R Biermasz Journal: Pituitary Date: 2015-10 Impact factor: 4.107
Authors: Wouter R van Furth; Amir H Zamanipoor Najafabadi; Merel van der Meulen; Marco J T Verstegen; Daniel J Lobatto; Maarten C Kleijwegt; Alberto M Pereira; Nienke R Biermasz Journal: Pituitary Date: 2022-01-10 Impact factor: 4.107
Authors: Cornelie D Andela; Daniel J Lobatto; Alberto M Pereira; Wouter R van Furth; Nienke R Biermasz Journal: Pituitary Date: 2018-04 Impact factor: 4.107
Authors: Tessa N A Slagboom; Jan Berend Deijen; Christa C Van Bunderen; Hans A Knoop; Madeleine L Drent Journal: Pituitary Date: 2021-02-19 Impact factor: 4.107
Authors: Cornelie D Andela; Margreet Scharloo; Steven Ramondt; Jitske Tiemensma; Olga Husson; Sofia Llahana; Alberto M Pereira; Ad A Kaptein; Noëlle G A Kamminga; Nienke R Biermasz Journal: Pituitary Date: 2016-06 Impact factor: 4.107